OptimizeRx Corp. (NASDAQ: OPRX), a provider of healthcare technology solutions for life sciences companies, announced that it has entered into a $35 million senior secured credit facility with Fifth Third Bank. The facility consists of a $25 million term loan and a $10 million revolving credit facility that was undrawn at closing. Roth Capital Partners served as financial advisor on the transaction.
This capital infusion is significant for OptimizeRx as it provides the company with additional financial resources to support its growth initiatives and operational needs. The credit facility enhances liquidity and offers flexibility for strategic investments, potential acquisitions, and working capital requirements. With the undrawn revolver, OptimizeRx has immediate access to $10 million for future needs, strengthening its balance sheet.
OptimizeRx is a leading healthcare technology company that is redefining how life science brands connect with patients and healthcare providers. The company’s platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, the company empowers brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
The importance of this announcement lies in the company's ability to scale its technology and expand its reach in the healthcare technology market. With a commitment to privacy-safe, patient-centric technology, OptimizeRx ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. The credit facility provides the necessary capital to continue developing these AI-driven solutions and maintain partnerships with some of the world’s leading pharmaceutical and life sciences companies.
Headquartered in Waltham, Massachusetts, OptimizeRx partners with top life sciences firms to transform the healthcare landscape and create a healthier future for all. The secured credit facility with Fifth Third Bank underscores the confidence financial institutions have in the company’s business model and growth trajectory. For investors and industry observers, this development signals that OptimizeRx is well-positioned to capitalize on growing demand for digital health engagement platforms.
The implications for the healthcare technology sector are notable. As life sciences companies increasingly seek efficient ways to engage patients and providers, OptimizeRx’s AI-powered platform offers a competitive advantage. The additional funding will likely accelerate product development and market penetration, potentially impacting how pharmaceutical companies approach patient outreach and treatment adherence.
For more information about OptimizeRx and its solutions, visit www.optimizerx.com.
